The National Cancer Institute periodically highlights a particular trial or group of trials out of more than 150 available cancer clinical trials conducted at the National Institutes of Health in Bethesda, Maryland.
Featured trials for a variety of different cancer topics include:
Clinical Trial(s)—Dr. Robert Yarchoan - View all Clinical Trials
- A Phase I/II Study of the Safety, Pharmacokinetics and Efficacy of Pomalidomide (CC-4047) in the Treatment of Kaposi Sarcoma in Individuals With or Without HIV
NCI-12-C-0047, NCT01495598
- Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi's Sarcoma
NCI-09-C-0130, NCT00923936
Clinical Trial(s)—Dr. Thomas Uldrick - View all Clinical Trials
- Pilot Study of Tocilizumab in Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV)-associated Multicentric Castleman Disease
NCI-11-C-0233, NCT01441063
Clinical Trial(s)—Dr. Wyndham H. Wilson - View all Clinical Trials
- Phase III Randomized Study of R-CHOP Versus Dose-Adjusted EPOCH-R With Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas
NCI-05-C-0252, NCT00118209
- Randomized Phase II Study of Dose-Adjusted EPOCH-Rituximab-Bortezomib Induction Followed by Bortezomib Maintenance Versus Observation in Untreated Mantle Cell Lymphoma With Microarray Profiling and Proteomics
NCI-05-C-0170, NCT00114738
Clinical Trial(s)—Dr. Kieron Dunleavy - View all Clinical Trials
- Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC Positive Diffuse Large B-Cell Lymphoma
NCI-10-C-0052, NCT01092182
Clinical Trial(s)—Dr. Thomas Waldmann - View all Clinical Trials
- Phase I/II Trial of Yttrium-90-labeled Daclizumab (anti-CD25) Radioimmunotherapy With High-dose BEAM Chemotherapy and Autologous Hematopoietic Stem Cell Rescue in Recurrent and Refractory Hodgkin's Lymphoma
NCI-12-C-0003, NCT01468311
Clinical Trial(s)—Dr. Steven A. Rosenberg - View all Clinical Trials
- Assessment of the Safety and Feasibility of Administering T cells Expressing an anti-CD19 Chimeric Antigen Receptor to Patients With B-cell Lymphoma or Leukemia
NCI-09-C-0082, NCT00924326
Clinical Trial(s)—Dr. James N. Kochenderfer - View all Clinical Trials
- Administration of Anti-CD19-Chimeric-Antigen-Receptor-Transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-Cell Malignancies After Allogeneic Stem Cell Transplantation
NCI-10-C-0054, NCT01087294
Clinical Trial(s)—Dr. Daniel H. Fowler - View all Clinical Trials
- Allogeneic HSCT Without Preparative Chemotherapy or With Low-Intensity Preparative Chemotherapy Using Sirolimus and Sirolimus Generated Donor Th2 Cells for Therapy of Refractory Leukemia, Lymphoma, Myeloma, or Myelodysplastic Syndrome
NCI-04-C-0055, NCT00074490
Clinical Trial(s)—Dr. Alan S. Wayne - View all Clinical Trials
- A Pilot Trial of WT1 Peptide-Loaded Allogeneic Dendritic Cell Vaccine and Donor Lymphocyte Infusion for WT1-Expressing Hematologic Malignancies
NCI-08-C-0051, NCT00923910
Clinical Trial(s)—Dr. Christina M. Annunziata - View all Clinical Trials
- Phase II Open Label Non-Randomized Single Agent Study of the SMAC (Second Mitochondrial-Derived Activator of Caspases)-Mimetic Birinapant (TL32711; NSC 756502) in Relapsed Platinum Resistant or Refractory Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
NCI-12-C-0191 , NCT01681368
Clinical Trial(s)—Dr. Tim F. Greten - View all Clinical Trials
- A Phase I/II Study of ISIS 183750 in Combination With Irinotecan in Irinotecan-refractory Colorectal Cancer
NCI-12-C-0187 , NCT01675128
Clinical Trial(s)—Dr. Raffit Hassan - View all Clinical Trials
- A Phase IB Study to Evaluate the Safety and Induction of Immune Response of CRS-207 in Combination With Pemetrexed and Cisplatin as Front-line Therapy in Adults with Malignant Pleural Mesothelioma
NCI-12-C-0170, NCT01675765
Clinical Trial(s)—Dr. William L. Dahut - View all Clinical Trials
- A Phase I Study of Cabozantinib (XL184) Plus Docetaxel and Prednisone in Metastatic Castrate Resistant Prostate Cancer
NCI-12-C-0204 , NCT01683994
- A Phase II Study of AMG 386 and Abiraterone in Metastatic Castration Resistant Prostate Cancer
NCI-12-C-0079, NCT01553188
- A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer
NCI-10-C-0062, NCT01090765
Clinical Trial(s)—Dr. James L. Gulley - View all Clinical Trials
- A Randomized, Double-Blind, Phase III Efficacy Trial of PROSTVAC-V/F Plus or Minus GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer
NCI-11-C-0262, NCT01322490
Clinical Trial(s)—Dr. Ravi A. Madan - View all Clinical Trials
- A Randomized Phase II Study of L-BLP25 in Combination With Standard Androgen Deprivation Therapy and Radiation Therapy for Newly Diagnosed, High Risk Prostate Cancer Patients
NCI-11-C-0247
- A Randomized Phase II Trial Combining Vaccine Therapy With PROSTVAC/TRICOM and Flutamide vs. Flutamide Alone in Men With Androgen Insensitive, Non-Metastatic (D0.5) Prostate Cancer
NCI-07-C-0107, NCT00450463
Search for other clinical trial summaries
Back to Top
